GSK3B and prostate cancer: The same effect was observed in LNCaP prostate cancer cells following GSK3β-K85R transfection (Supplementary Figure S1A), and was corroborated by a 50% reduction in levels of the same mature miRs following 99021 treatment of LNCaP cells (Supplementary Figure S1B).